• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Report: Personalized Medicine Is Having A Positive Measurable Effect on Patient Outcomes

by HITC Staff 03/01/2016 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

SAP Personalized Medicine

A new approach to research, pharmaceutical development, and clinical care is remaking healthcare. Known as personalized medicine or precision medicine, it promises improved patient outcomes, cost savings, and progress against previously intractable illnesses.

Yet substantial challenges remain to be addressed if personalized medicine is to deliver on its potential. A new research program from Oxford Economics shows what healthcare and pharmaceutical organizations are doing to hasten this revolution—and what they must do to move it forward. The research, sponsored by SAP, includes a survey of 120 healthcare professionals at institutions in Europe and North America, along with in-depth interviews with experts in the field.

Built on genomic science and Big Data technology, personalized medicine moves beyond the familiar one-size-fits-all model of prevention, diagnosis, and treatment toward mass customization and in some cases individualized delivery of care. Among the key findings of the research:

  • Over two-thirds of survey respondents say personalized medicine is already having a measurable effect on patient outcomes, and roughly the same number say it will have an impact on their organization in the next two years.
  • Meaningful adjustments to culture and governance are required. Yet organizations are still learning to share data and interact with newly empowered patients, while preparation for regulatory changes remains a work in progress.
  • Technology is at the heart of personalized medicine, and substantial investments are being made in Big Data and analytics. Building out IT capabilities is an essential next step.
  • Business models are not fully developed, but the economic case for personalized medicine is maturing; optimism abounds about revenue growth and profitability over the next two years.

“Personalized medicine offers better and more efficient ways to address a wide range of challenging medical issues,” says Edward Cone, Deputy Director of Thought Leadership and Technology Practice Lead at Oxford Economics. “At the same time, there remains a lot of work to be done on the details of governance, culture, and information technology.”

The full report will be available in March. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Personalized Medicine

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |